Medidata Appoints New Chief Strategy Officer to Drive AI-Powered Clinical Trial Innovation

Medidata, a leading clinical trial technology company, has announced the appointment of Lisa Moneymaker as its new Chief Strategy Officer. This strategic move aims to bolster the company's efforts in developing AI-powered products and enhancing clinical trial experiences.

Industry Veteran Takes the Helm

Lisa Moneymaker, previously serving as Medidata's Senior Vice President of Strategic Customer Engagement, brings a wealth of experience to her new role. With a career spanning over two decades in the pharmaceutical and clinical research sectors, Moneymaker's expertise is expected to play a crucial role in shaping Medidata's future vision.

Anthony Costello, CEO of Medidata, expressed confidence in Moneymaker's appointment, stating, "Lisa's proven leadership within the field and profound grasp of the intricate relationship between technology and clinical research perfectly align with our strategic imperatives and future vision."

A Focus on Innovation and Customer-Centric Solutions

In her new position, Moneymaker will lead Medidata's strategy team, focusing on the development of AI-powered products and innovative clinical trial experiences. This move underscores the company's commitment to implementing cutting-edge solutions that address the evolving needs of the pharmaceutical industry.

Medidata's strategy organization, under Moneymaker's leadership, is set to prioritize customer needs and industry advancement. The company believes that this approach is essential for its success and contribution to the broader pharmaceutical sector.

A Career Marked by Expertise and Leadership

Moneymaker's journey in the pharmaceutical industry began at Amgen, where she worked for 18 years, starting as a product lead. Her first tenure at Medidata lasted three years before she briefly departed to serve as the Chief Strategy Officer at Saama, an AI clinical analytics company. Moneymaker's return to Medidata in October 2024 and subsequent promotion highlight the company's recognition of her valuable industry insights and leadership capabilities.

As the pharmaceutical industry continues to embrace technological advancements, Medidata's strategic appointment of Lisa Moneymaker signals its commitment to remaining at the forefront of clinical trial innovation and AI-driven solutions.